Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy
- 1 November 2004
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 66 (92) , S115-S117
- https://doi.org/10.1111/j.1523-1755.2004.09228.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Losartan Reduces the Costs Associated With Diabetic End-Stage Renal DiseaseDiabetes Care, 2003
- Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European UnionKidney International, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Prevention of End-Stage Renal Disease Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Medicare's End-Stage Renal Disease Program: Current Status And Future ProspectsHealth Affairs, 1999
- Renal disease and hypertension in non–insulin-dependent diabetes mellitusKidney International, 1999
- Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projectionsDiabetes Care, 1998